Sigachi Industries Limited (SIGACHI)

Loading page…

Sigachi Industries Limited (SIGACHI) · mywealthgrid

About

Sigachi Industries Limited is a pharmaceutical company operating in India's Healthcare sector, with market cap of ₹1,042 Cr. Recent quarters exhibit significant volatility in profitability, ranging from −₹0.02 Cr net profit to ₹11.76 Cr, and operating margins from 4.88% to 13.61%. The stock has declined 16.55% over 12 months, reflecting concern about operational consistency.

Face value: ₹1

Market cap

₹1,083 Cr

P/E

42.7×

P/B

2.1×

Dividend yield

0.4%

ROE

-14.6%

ROCE

7.2%

Debt / equity

0.26

OPM

11.3%

EPS (TTM)

₹0.7

Book value

₹13.7

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Negative ROE of −14.57% with one recent quarter (Dec 2025) reporting near-zero profit (−₹0.02 Cr); verify whether profitability is stabilizing
Operating margin compressed to 4.88% in Dec 2025 from 13%+ in nearby quarters; verify root cause and consistency of operational control
52-week stock price range of ₹16.92–₹44.38 reflects high volatility; verify whether fundamental or sentiment-driven
Minimal institutional participation (FII 1.25%, DII 0%) with 62% public shareholding; verify concentration risk and holder stability

Generated analysis · source review pending

Growth drivers

Recent revenue of ₹121.27 Cr (Jun 2026) recovered from ₹83.94 Cr (Sep 2025), a 44% sequential increase; verify if structural or seasonal
Operating margin and EPS both sharply improved in Jun 2026 (13.61% OPM, ₹0.18 EPS) from Dec 2025 lows (4.88% OPM, ₹0.01 EPS); verify if cost control, volume growth, or temporary
Verify pharmaceutical sector growth drivers and Sigachi's competitive positioning within high-growth subsegments

Generated analysis · source review pending

1,203 historical price candles were omitted because the exchange source has not been verified.

₹28.3-1.5%1Y

Quick read

rule-based

Pros

+Revenue CAGR of 16.5% over the last 3 years

Cons

−Low return on equity of 5.1% (3-yr avg)
−Promoter holding fell 7.5 pts over the last year

Research score

Structured signal from quality, growth, valuation and momentum.

34/100

Business quality: 26
Growth: 33
Valuation: 42

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	250	302	399	488	478
COGS	119	138	195	222	248
Gross profit	132	164	204	266	230
	79	105	127	166	176
	53	59	77	100	54
OPM %	21.2%	19.4%	19.2%	20.5%	11.3%
Depreciation	3	7	11	16	18
Interest	1	4	8	12	14
	3	7	12	21	-110
Profit before tax	52	54	70	92	-88
Tax	12	11	13	22	-5
Tax %	22.4%	20.1%	17.9%	23.7%	-5.6%
	40	44	57	70	-83
PAT margin %	16%	14.4%	14.4%	14.4%	-17.3%
EPS (₹)	15.4	14.2	1.8	2.1	-2.1
EPS adjusted (₹)	1.3	1.4	1.7	1.8	-2.1
	0%	14.1%	5.5%	4.9%	—
Annual report	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	31	31	33	38	38
Reserves	197	238	397	563	484
Minority interest	—	—	11	12	7
	34	40	143	142	136
	25	65	110	91	177
Total equity & liabilities	287	374	694	846	841
	53	122	227	344	296
CWIP	10	35	97	9	31
Investments	0	0	0	0	0
	224	216	371	494	515
Total assets	287	374	694	846	841

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	6	29	13	27	4
	-63	-92	-161	-93	-53
	108	26	172	81	2
Net cash flow	51	-37	24	15	-46
Free cash flow	-18	-72	-72	-16	-37
CFO / Operating profit %	11%	49.4%	16.8%	26.9%	8%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	52.6%	54.2%	51.1%	54.5%	48.2%
EBITDA margin %	21.2%	19.4%	19.2%	20.5%	11.3%
EBIT margin %	20%	17.2%	16.5%	17.2%	7.6%
PAT margin %	16%	14.4%	14.4%	14.4%	-17.3%
Working capital
Receivable days	88	97	137	137	171
Inventory days	94	123	132	155	108
Payable days	33	55	90	59	87
NWC days	149	165	180	234	193
Leverage
Current ratio	3.5	2.38	1.67	2.13	1.44
Debt to EBITDA	0.65	0.69	1.87	1.42	2.52
Debt to equity	0.15	0.15	0.33	0.24	0.26
Interest coverage	45.1	13.7	10	8.4	3.2
Asset turnover	0.87	0.81	0.57	0.58	0.57
Return ratios
Return on assets %	14%	11.6%	8.3%	8.3%	-9.8%
Return on capital employed %	22.4%	22%	19.3%	17.9%	7.2%
Return on equity %	17.6%	16.2%	13.3%	11.7%	-15.9%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	46.08%	48.49%	45.43%	45.43%	44.71%	44.71%	44.14%	44.14%	40.48%	39.7%	36.69%	36.69%
	2.46%	0.22%	2.06%	1.56%	1.58%	0.16%	0.08%	2.89%	3.1%	3.33%	1.3%	1.25%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	51.46%	51.29%	52.51%	53.01%	53.71%	55.13%	55.78%	52.97%	56.42%	56.97%	62.01%	62.06%
No. of shareholders	—	—	—	—	—	—	—	—	2,05,266	1,94,777	1,94,559	1,88,986

Promoter holding down 9.39 percentage points since Sep 2023.

3 disclosures

Person	Deal	Shares	Value	Holding	Filed
Amit Raj SinhaPromoters	SellMarket Sale	12,07,914	₹3.82 cr	3.98% → 3.66%	13 Sept 20257(2)
Amit Raj SinhaPromoters	SellMarket Sale	73,02,108	₹23.18 cr

203 deals · 24 Nov 2021 – 18 Sept 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
18 Sept 2026	SPDR PORTFOLIO EMERGING MARKETS ETF	Bulk	NSE	Sell	37,32,647	₹29.83	₹11.13 Cr
28 Jan 2026	ANURAG REDDY NARREDDY	Bulk	NSE	Sell	20,00,000	₹20.03	₹4.01 Cr
27 Jan 2026	ANURAG REDDY NARREDDY	Bulk	NSE	Sell	35,00,000	₹20.42	₹7.15 Cr
27 Jan 2026	VIJAY AMRUTLAL BHAVSAR	Bulk	NSE	Sell	24,73,605	₹20.60	₹5.10 Cr
22 Jan 2026	ALGOQUANT FINTECH LIMITED	Bulk	NSE	Buy	29,86,586	₹22.97	₹6.86 Cr
22 Jan 2026	ALGOQUANT FINTECH LIMITED	Bulk	NSE	Sell	29,86,052	₹23.01	₹6.87 Cr
22 Jan 2026	KETAN HASMUKHLAL DOSHI	Bulk	NSE	Sell	26,81,879	₹23.09	₹6.19 Cr
22 Jan 2026	KETAN HASMUKHLAL DOSHI	Bulk	NSE	Buy	1,00,000	₹24.43	₹0.24 Cr
20 Jan 2026	ANURAG REDDY NARREDDY	Bulk	NSE	Sell	20,00,000	₹24.49	₹4.90 Cr
9 Jan 2026	KETAN HASMUKHLAL DOSHI	Bulk	NSE	Buy	56,83,619	₹29.91	₹17.00 Cr

1–10 of 203

1 / 21

Mr. Amit Raj SinhaExecutive Director-Chairperson-CEO-MD
Mr. Rabindra Prasad SinhaExecutive Director
Mr. ChidambaranathanExecutive Director
Ms. Dhanalakshmi GuntakaNon-Executive - Independent Director
Ms. Bindu VinodhanNon-Executive - Independent Director
Mr. Janardhana Reddy YeddulaNon-Executive - Independent Director
Mr. Vivek KumarCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 1 fund houses

Held by these funds

of the company's equity

All mutual funds

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

1 schemes

		Shares
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	6,604	0.02	0.05%	0.002%	+10

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Aug 2026Transcript AI SummaryPPTREC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

5

Final dividend22 Sept 2026 · ex-date₹0.1
Final dividend16 Sept 2025 · ex-date₹0.1
Final dividend28 Aug 2024 · ex-date₹0.1
Final dividend31 Aug 2023 · ex-date₹1
Interim dividend2 Aug 2022 · ex-date₹1

2

Board meeting to consider results13 Aug 2026
Board meeting to consider results27 Jul 2026

1

Face value ₹10 → ₹19 Oct 2023 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

30 announcementsExport CSV

30 Sept 2026, 6:03 pmCompany Update

List Of Dissenting Shareholders

General PDF

30 Sept 2026, 5:49 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

29 Sept 2026, 3:56 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

28 Sept 2026, 5:52 pmCompany Update

Sustainability Report For The Financial Year Ended March 31, 2026

General PDF

16 Sept 2026, 3:51 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

EGM PDF

15 Sept 2026, 3:39 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of EGM

EGM PDF

11 Sept 2026, 9:37 amCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

9 Sept 2026, 3:38 pmAGM/EGM

Corrigendum To The Notice Of Extraordinary General Meeting To Be Held On Tuesday,September 15, 2026 At 11.00 Am

EGM PDF

Date	Category	Subject	Filing
30 Sept 2026, 6:03 pm	Company Update General	List Of Dissenting Shareholders	PDF
30 Sept 2026, 5:49 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF

Loading announcements…

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	52.6%	54.2%	51.1%	54.5%	48.2%
EBITDA margin %	21.2%	19.4%	19.2%	20.5%	11.3%
EBIT margin %	20%	17.2%	16.5%	17.2%	7.6%
PAT margin %	16%	14.4%	14.4%	14.4%	-17.3%
Working capital
Receivable days	88	97	137	137	171
Inventory days	94	123	132	155	108
Payable days	33	55	90	59	87
NWC days	149	165	180	234	193
Leverage
Current ratio	3.5	2.38	1.67	2.13	1.44
Debt to EBITDA	0.65	0.69	1.87	1.42	2.52
Debt to equity	0.15	0.15	0.33	0.24	0.26
Interest coverage	45.1	13.7	10	8.4	3.2
Asset turnover	0.87	0.81	0.57	0.58	0.57
Return ratios
Return on assets %	14%	11.6%	8.3%	8.3%	-9.8%
Return on capital employed %	22.4%	22%	19.3%	17.9%	7.2%
Return on equity %	17.6%	16.2%	13.3%	11.7%	-15.9%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Sigachi Industries Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Insider dealing

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Dividends5

Board meetings2

Stock splits1

Announcements

Not in the F&O segment

Dividends5

Board meetings2

Stock splits1

Ratio timeline

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Quarterly record

Insider dealing

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

5

2

1

5

2

1